Figure 5.

Differential gene expression pattern in Paclitaxel-surviving cells. (A) Differential mRNA expression levels of stemness- and mesenchymal-associated genes between primary tumors (not exposed to Paclitaxel) and recurrent tumors (following Paclitaxel). n = 10 animals per group; blue arrows point to tumors analyzed. (B-i) Flow cytometry analysis comparing CD44 levels in primary and recurrent tumors. Note the enrichment of CD44+ cells in recurrent tumors. (ii) Differential levels of protein expression in primary and recurrent tumors determined by Western blot analysis. Data shown are representative of three independent experiments (n = 10 animals per group). (C) Vimentin expression was compared between Control/primary tumors and Treated/recurrent tumors using immunohistochemistry. Data shown are representative of three independent experiments (n = 10 animals per group). (D) High levels of vimentin were also observed in samples from recurrent epithelial ovarian cancer (EOC) patients. Images are representative of immunohistochemistry staining from two patients. *P < 0.001.